AllianceBernstein’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

AllianceBernstein’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-63,970	Closed	-$614K	–	3265
2024 Q4	$614K	Buy	63,970 +18,340	+40%	+$95.7K	﹤0.01%	2544
2024 Q3	$131K	Buy	45,630 +3,670	+9%	+$11.4K	﹤0.01%	3101
2024 Q2	$123K	Buy	41,960 +23,290	+125%	+$63.7K	﹤0.01%	3097
2024 Q1	$59.6K	Hold	18,670	–	–	﹤0.01%	3074
2023 Q4	$62.7K	Hold	18,670	–	–	﹤0.01%	3117
2023 Q3	$44.4K	Buy	18,670 +5,530	+42%	+$11.6K	﹤0.01%	3145
2023 Q2	$23.1K	Buy	+13,140	New	+$33.6K	﹤0.01%	3153

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AllianceBernstein's PSTX Position: Q1 2025 in Review

AllianceBernstein sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 63,970 shares — an estimated $614K sold.

AllianceBernstein first reported a position in PSTX in Q2 2023 and held it in 7 quarters. The position peaked at $614K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

AllianceBernstein reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
AllianceBernstein sold 63,970 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $614K.
AllianceBernstein first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2023 and held it in 7 quarters.
AllianceBernstein's Poseida Therapeutics, Inc. Common Stock position peaked at $614K in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on AllianceBernstein's 13F filing for Q1 2025, filed 15 May 2025.